KCNQ1OT1 hypomethylation: A Novel disguised genetic predisposition in sporadic pediatric adrenocortical tumors?

2011 ◽  
Vol 59 (3) ◽  
pp. 565-566 ◽  
Author(s):  
Mark Wijnen ◽  
Mariëlle Alders ◽  
Christian M. Zwaan ◽  
Anja Wagner ◽  
Marry M. van den Heuvel-Eibrink
2014 ◽  
Vol 61 (11) ◽  
pp. 1940-1948 ◽  
Author(s):  
Fabíola A. Leite ◽  
Regia C. P. Lira ◽  
Paola F. Fedatto ◽  
Sonir R. R. Antonini ◽  
Carlos E. Martinelli ◽  
...  

2015 ◽  
Vol 50 (8) ◽  
pp. 1323-1328 ◽  
Author(s):  
André Ivan Bradley dos Santos Dias ◽  
Camila Girardi Fachin ◽  
Lucimar Retto Silva Avó ◽  
Caio Vinicius Gonçalves Frazão ◽  
Eliana Maria Monteiro Caran ◽  
...  

2008 ◽  
Vol 14 (12) ◽  
pp. 4016-4024 ◽  
Author(s):  
Rossella Libé ◽  
Amato Fratticci ◽  
Joel Coste ◽  
Frédérique Tissier ◽  
Anelia Horvath ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6111
Author(s):  
Karina C. F. Tosin ◽  
Edith F. Legal ◽  
Mara A. D. Pianovski ◽  
Humberto C. Ibañez ◽  
Gislaine Custódio ◽  
...  

The incidence of pediatric adrenocortical tumors (ACT) is high in southern Brazil due to the founder TP53 R337H variant. Neonatal screening/surveillance (NSS) for this variant resulted in early ACT detection and improved outcomes. The medical records of children with ACT who did not participate in newborn screening (non-NSS) were reviewed (2012–2018). We compared known prognostic factors between the NSS and non-NSS cohorts and estimated surveillance and treatment costs. Of the 16 non-NSS children with ACT carrying the R337H variant, the disease stages I, II, III, and IV were observed in five, five, one, and five children, respectively. The tumor weight ranged from 22 to 608 g. The 11 NSS children with ACT all had disease stage I and were alive. The median tumor weight, age of diagnosis, and interval between symptoms and diagnosis were 21 g, 1.9 years, and two weeks, respectively, for the NSS cohort and 210 g, 5.2 years, and 15 weeks, respectively, for the non-NSS cohort. The estimated surveillance/screening cost per year of life saved is US$623/patient. NSS is critical for improving the outcome of pediatric ACT in this region. Hence, we strongly advocate for the inclusion of R337H in the state-mandated universal screening and surveillance.


2016 ◽  
Vol 05 (04) ◽  
pp. 109-114
Author(s):  
Lucia Salvatorelli ◽  
Giuseppe Angelico ◽  
Fabio Motta ◽  
Andrea Di Cataldo ◽  
Pietro Milone ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document